{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Spigel DR"],"funding":["NCI NIH HHS"],"pagination":["1301-1311"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9015199"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(12)"],"pubmed_abstract":["<h4>Purpose</h4>The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant improvements in the primary end points of overall survival (OS; stratified hazard ratio [HR], 0.68; 95% CI, 0.53 to 0.87; <i>P</i> = .00251) and progression-free survival (PFS [blinded independent central review; RECIST v1.1]; stratified HR, 0.52; 95% CI, 0.42 to 0.65; <i>P</i> < .0001), with manageable safety. We report updated, exploratory analyses of survival, approximately 5 years after the last patient was randomly assigned.<h4>Methods</h4>Patients with WHO performance status 0 or 1 (any tumor programmed cell death-ligand 1 "],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer."],"pmcid":["PMC9015199"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Vansteenkiste JF","Naidoo J","Reck M","Garassino MC","Spigel DR","Gray JE","Rimner A","Wu YL","Vicente D","Quantin X","Cho BC","Newton M","Faivre-Finn C","Kurata T","Hui R","Paz-Ares L","Senan S","Antonia SJ","Kato T","Thiyagarajah P","de Wit M","Mann H","Ozguroglu M","Planchard D","Lee KH"],"additional_accession":[]},"is_claimable":false,"name":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.","description":"<h4>Purpose</h4>The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant improvements in the primary end points of overall survival (OS; stratified hazard ratio [HR], 0.68; 95% CI, 0.53 to 0.87; <i>P</i> = .00251) and progression-free survival (PFS [blinded independent central review; RECIST v1.1]; stratified HR, 0.52; 95% CI, 0.42 to 0.65; <i>P</i> < .0001), with manageable safety. We report updated, exploratory analyses of survival, approximately 5 years after the last patient was randomly assigned.<h4>Methods</h4>Patients with WHO performance status 0 or 1 (any tumor programmed cell death-ligand 1 ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-20T00:18:15.46Z","creation":"2025-02-19T01:53:29.024Z"},"accession":"S-EPMC9015199","cross_references":{"pubmed":["35108059"],"doi":["10.1200/JCO.21.01308"]}}